Actinic (Solar) Keratosis - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis - Overview
Actinic (Solar) Keratosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Athenex Inc
CritiTech Inc
Foamix Pharmaceuticals Ltd
G&E Herbal Biotechnology Co Ltd
Galderma SA
Laboratories Ojer Pharma SL
LEO Pharma A/S
Novartis AG
Oncology Research International Ltd
Promius Pharma LLC
Valeant Pharmaceuticals International Inc
Vectura Group Plc
Actinic (Solar) Keratosis - Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-17137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-695 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide + sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDP-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDP-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol disoxate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORIL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKP-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDA-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion
Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis
Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment
Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2017
Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2017
Actinic (Solar) Keratosis - Pipeline by CritiTech Inc, H1 2017
Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
Actinic (Solar) Keratosis - Pipeline by Galderma SA, H1 2017
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2017
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2017
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2017
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2017
Actinic (Solar) Keratosis - Pipeline by Promius Pharma LLC, H1 2017
Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H1 2017
Actinic (Solar) Keratosis - Dormant Projects, H1 2017
Actinic (Solar) Keratosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Actinic (Solar) Keratosis - Discontinued Products, H1 2017